Design Therapeutics, Inc. 8K

Design Therapeutics reported Q2 2026 results, outlined RESTORE-FA trial modifications and pipeline progress, and noted a $207.4 million cash position supporting ongoing GeneTAC programs.

Design Therapeutics, Inc. filed a Form 8-K to announce second quarter 2026 financial results and provide a clinical development update across its GeneTAC portfolio, highlighting positive four-week RESTORE-FA data for DT-216P2 in Friedreich ataxia that support trial modifications (including setting endogenous frataxin protein change as the primary efficacy endpoint, continuing at a 1 mpk dose with an expanded 12-week cohort, and exploring a higher dose), the initiation of patient dosing in a Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1, ongoing Phase 2 biomarker work with DT-168 in Fuchs endothelial corneal dystrophy now delayed to 2027 due to supply issues, continued preclinical work in Huntington’s disease, and a financial position as of June 30, 2026 showing a $20.2 million quarterly net loss and $207.4 million in cash, cash equivalents and investment securities that management believes provide a strong runway.

Filing Facts

CIK

1807120

Ticker

DSGN

Form

8K

Source Type

fda

Accession

0001193125-26-329570

Alert Tier

6